HighGravityDataInsulet — May 6, 2026 release
Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001145197-26-000100
Showing in the filing
U.S. Omnipod Revenue Growth - Constant Currency
“20% - 22%”
Period
FY2026
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 25
International Omnipod Revenue Growth - Curre… for FY2026
“3%”
U.S. Omnipod Revenue Growth (Constant Curren… for Q2 FY2026
“18% - 20%”
International Omnipod Revenue Growth (Curren… for Q2 FY2026
“2%”
International Omnipod Revenue Growth (Consta… for Q2 FY2026
“28% - 30%”
International Omnipod for Q2 FY2026
“28% - 30%”
Total Omnipod Revenue Growth (Constant Curre… for Q2 FY2026
“21% - 23%”
Total Omnipod for Q2 FY2026
“21% - 23%”
Total Omnipod Revenue Growth (Currency Impact) for Q2 FY2026
“1%”
Drug Delivery Revenue Growth (Constant Curre… for Q2 FY2026
“~(50)%”
Drug Delivery for Q2 FY2026
“~(50)%”
Adjusted Operating Margin for Q2 FY2026
“~100 bps YoY expansion”
Adjusted EPS Growth for Q2 FY2026
“>25%”
Total Revenue Growth (Constant Currency) for Q2 FY2026
“20% - 22%”
U.S. Omnipod Revenue Growth - Constant Curre… for FY2026
“20% - 22%”
International Omnipod Revenue Growth - GAAP for FY2026
“29% - 31%”
International Omnipod Revenue Growth - Const… for FY2026
“26% - 28%”
International Omnipod for FY2026
“26% - 28%”
Total Omnipod Revenue Growth - GAAP for FY2026
“23% - 25%”
Total Revenue Growth - GAAP for FY2026
“22% - 24%”
Total Revenue Growth - Constant Currency for FY2026
“21% - 23%”
Total Revenue Growth (GAAP) for Q2 FY2026
“21% - 23%”
International Omnipod Revenue Growth (GAAP) for Q2 FY2026
“30% - 32%”
Total Omnipod Revenue Growth - Constant Curr… for FY2026
“22% - 24%”
Total Omnipod Revenue Growth (GAAP) for Q2 FY2026
“22% - 24%”
Total Omnipod for FY2026
“22% - 24%”
Exhibit 99.1 · the passage around this item
… earlier in the release
Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. 10 INSULET CORPORATION NON-GAAP RECONCILIATIONS (UNAUDITED) CONTINUED REVENUE GUIDANCE Year Ending December 31, 2026 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 20% - 22% —% 20% - 22% International Omnipod 29% - 31% 3% 26% - 28% Total Omnipod 23% - 25% 1% 22% - 24% Drug Delivery ~(50)% —% ~(50)% Total 22% - 24% 1% 21% - 23% Three Months Ended June 30, 2026 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 18% - 20% —% 18% - 20% International Omnipod 30% - 32% 2% 28% - 30% Total Omnipod 22% - 24% 1% 21% - 23% Drug Delivery ~(50)% —% ~(50)% Total 21% - 23% 1% 20% - 22% 11
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.